PRELIMINARY PROGRAM update 13/10/2020

Course DirectorsClaus Garbe, Tuebingen, Germany

Axel Hauschild, Kiel, GermanyDavid Moreno-Ramirez, Seville, Spain

Iris Zalaudek, Trieste, Italy

9th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY UPDATE ON CUTANEOUS ONCOLOGY (ESDO)JANUARY 15th–16th, 2021V I R T UA L

European Association of Dermato-Oncology (EADO) 2

Target Audience 2

Educational Objectives 2

Course Organization 3

Program Overview 4

Program 6

Friday, January 15th, 2021 6

Saturday, January 16th, 2021 8

Invited Course Faculty 10General Information 13

www.dermato-oncology2021.org

Content

2

European Association of Dermato-Oncology (EADO)

The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and sec-ondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website (www.eado.org).The EADO initiates for the ninth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease.

Target Audience

This 2-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

Educational Objectives

The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of locoregional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge:

1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy.

2. The indications, risks and benefits and strategies for mole screening.

3. Diagnosis of skin cancer: how to break bad news.

3

4. The indications and methods for genetic diagnosis and genetic counseling of skin cancer patients.

5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.

6. The value of imaging and biomarkers for the detection of metastases and disease staging.

7. Adjuvant treatment of skin cancer: radiotherapy, immunotherapy, chemotherapy.

8. New systemic treatments for stage IV melanoma: targeted agents and immuno-therapeutics.

9. New treatment options of advanced basal cell carcinoma.

10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma.

11. The characteristics of mucosal and uveal melanomas and their treatment options.

12. Options for topical treatment of epithelial skin cancers.

13. The current classification of cutaneous lymphoma, staging and treatment options for different subtypes of cutaneous lymphoma.

14. Clinical trials in skin cancer: an update.

15. The indications and strategies for supportive treatments including best supportive care.

Course Organization

The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained. The main part of the course consists of 6 interactive sessions. Every participant takes part in each of these sessions which mainly comprise case-based discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made.

We look forward to welcoming you in January 2021!

Claus Garbe, MD Axel Hauschild, MDDavid Moreno-Ramirez, MDIris Zalaudek, Trieste, MD Course Directors

4

8:00 9:00 10:00 11:00 12:00

Friday January 15th, 2021

Wel

com

e Se

ssio

n PLENARY SESSION 1:

C. GarbeA. M. ForseaJ. J. GrobI. ZalaudekT. Dirschka

Bre

ak

Bre

ak

COURSE A

Franz Trautinger

COURSE B

David Moreno-Ramirez

Saturday January 16th, 2021

Non-Melanoma Skin Cancer Day

Melanoma Day

Program Overview

PLENARY SESSION 4:

I. Zalaudek A. Lallas J. Malvehy H. Kittler B

reak

COURSE D

Jessica Hassel

COURSE E

Claus GarbeB

reak

13:00 14:00 15:00 16:00 17:00 18:00

Friday January 15th, 2021

PLENARY SESSION 2:

K. Peris U. Leiter C. Lebbé R. KaufmannT. Dirschka

PLENARY SESSION 3:

P. Arenberger V.del Marmol J. Oláh

Bre

ak

Bre

ak

Bre

akCOURSE B

David Moreno-Ramirez

COURSE C

Axel Hauschild

Saturday January 16th, 2021

PLENARY SESSION 5:

A. Hauschild C. Höller

PLENARY SESSION 6:

L. Kandolf-Sekulovic C. Lebbé J. Hassel

COURSE E

Claus Garbe

COURSE F

Reinhard DummerB

reak

Bre

ak

Bre

ak

6

Friday, January 15th, 2021

Non-Melanoma Skin Cancer Day

08:45 –09:00 Welcome and course introduction Claus Garbe, Tuebingen, Germany

PLENARY SESSION 1: NMSC: What’s new? Chairpersons: Jean Jacques Grob and Ana-Maria Forsea

09:00 –09:20 LECTURE 1: Epidemiology Claus Garbe, Tuebingen, Germany

09:20 –09:40 LECTURE 2: Classification of cutaneous squamous cell carcinoma Ana-Maria Forsea, Bucharest, Romania

09:40 –10:00 LECTURE 3: Classification of advanced basal cell carcinoma Jean Jacques Grob, Marseille, France

10:00 –10:20 LECTURE 4: Locally advanced NMSC from a patient’s perspective Iris Zalaudek, Trieste, Italy

10:20 –10:40 LECTURE 5: What is new for actinic keratosis? Thomas Dirschka, Wuppertal, Germany

10:40 –11:00 Discussion

11:00 –11:15 Break

11:15 –12:15 COURSE A: Treatment of cutaneous lymphomas: Guidelines and more Franz Trautinger, St. Poelten, Austria

12:15 –12:30 Break

12:30 –13:30 COURSE B: Surgical pearls in the treatment of NMSC David Moreno-Ramirez, Seville, Spain

Program

13:30 –13:45 Break

13:45 –14:45 COURSE C: Adjuvant, neoadjuvant and palliative immunotherapies for NMSC Axel Hauschild, Kiel, Germany

14:45 –15:00 Break

PLENARY SESSION 2: Guideline-based diagnosis and treatment of NMSC Chairpersons: Ketty Peris and Ulrike Leiter

15:00 –15:20 LECTURE 6: Basal cell carcinoma Ketty Peris, Rome, Italy

15:20 –15:40 LECTURE 7: Squamous cell carcinoma Ulrike Leiter, Tuebingen, Germany

15:40 –16:00 LECTURE 8: Merkel cell carcinoma Celeste Lebbé, Paris, France

16:00 –16:20 LECTURE 9: Dermatofibrosarcoma protuberans Roland Kaufmann, Frankfurt, Germany

16:20 –16:40 Discussion

16:40 –17:00 Break

17:00 –18:00 PLENARY SESSION 3: Difficult to treat non-melanoma skin cancers · Interactive case discussion Presenter: Petr Arenberger, Veronique del Marmol, Judit Oláh

8

Saturday, January 16th, 2021

Melanoma Day

Program

PLENARY SESSION 4: Early detection of melanoma Chairpersons: Iris Zalaudek and Joseph Malvehy

09:00 –09:20 LECTURE 10: Dermoscopy of pigmented lesions Iris Zalaudek, Trieste, Italy

09:20-09:40 LECTURE 11: Dermoscopy of non-pigmented lesions Aimilios Lallas, Thessaloniki, Greece

09:40-10:00 LECTURE 12: Skin cancer apps: ready for prime time? Josep Malvehy, Barcelona, Spain

10:00-10:20 LECTURE 13: New studies on artificial intelligence Harald Kittler, Vienna, Austria

10:20 –10:40 Discussion

10:40 –11:00 Break

11:00 –12:00 COURSE D: Management of adverse events of ICI and targeted therapies Jessica Hassel, Heidelberg, Germany

12:00 –12:15 Break

12:15 –13:15 COURSE E: Management of melanoma patients stages I–III: surgery, irradiation and adjuvant systemic treatment Claus Garbe, Tuebingen, Germany

13:15 –13:30 Break

13:30 –14:30 COURSE F: Targeted therapies, immunotherapies and combinations for advanced metastatic melanomas Reinhard Dummer, Zurich, Switzerland

14:30 –14:45 Break

PLENARY SESSION 5: Perspectives in metastatic melanoma Chairpersons: Roland Kaufmann and Iris Zalaudek

14:45 –15:15 LECTURE 14: Neoadjuvant melanoma treatment: replacing surgery soon? Axel Hauschild, Kiel, Germany

15:15–15:45 LECTURE 15: Is stage IV melanoma a curable disease? Christoph Höller, Vienna, Austria

15:45 –16:00 Break

16:00 –17:00 PLENARY SESSION 6: Difficult to treat melanomas · Interactive case discussion Presenter: Lidija Kandolf-Sekulovic, Celeste Lebbé, Jessica Hassel

10

A

Petr Arenberger, MDProfessor of Dermatology, Director Department of DermatologyCharles University3rd School of MedicineSrobarova 50Prague, Czech RepublicEmail: avemedica@email.cz

D

Veronique Del Marmol, MDDepartment of Clinical ChemistryErasme Hospital – ULBRoute de Lennik 8081070 Brussels, Belgium

Thomas Dirschka, MDCentroDermPrivate practiceHeinz-Fangmann-Str. 57Wuppertal, GermanyEmail: info@centroderm.de

Reinhard Dummer, MDDepartment of DermatologyUniversity of ZurichHospitalGloriastrasse 31Zurich, Switzerland Email: reinhard.dummer@usz.ch

F

Ana-Maria Forsea, MDAssociate Professor for DermatologyDepartment of DermatologyCarol Davila University of Medicineand Pharmacy BucharestBulevardul Eroii Sanitari 8Bucharest, RomaniaEmail: aforsea@yahoo.com

G

Claus Garbe, MDProfessor of DermatologyDepartment of DermatologyEberhard Karls University Liebermeister Str. 25Tuebingen, GermanyEmail: claus.garbe@med.uni-tuebingen.de

Jean Jacques Grob, MDProfessor of DermatologyService de Dermatology and Cancer ResearchHôpital de la Timone 264 Rue St. Pierre Marseille, FranceEmail: jean-jacques.grob@ap-hm.fr

Invited Course Faculty

11

H

Jessica Hassel, MDDepartment of Dermatology, UniversityHospital Heidelberg and NationalesCentrum für Tumorerkrankungen (NCT)Im Neuenheimer Feld 460Heidelberg, GermanyEmail: jessica.hassel@med.uniheidelberg.de

Axel Hauschild, MDProfessor of Dermatology Department of Dermatology University of Kiel Rosalind-Franklin-Str. 7Kiel, GermanyEmail: ahauschild@dermatology.uni-kiel.de

Christoph Höller, MDProfessor of DermatologyDepartment of Dermatology Medical University of Vienna Waehringer Guertel 18–20Vienna, AustriaEmail: christoph.hoeller@meduniwien. ac.at

K

Lidija Kandolf Sekulovic, MDProfessor of DermatologyDepartment of DermatologyMedical FacultyMilitary Medical AcademyCrnotravska 17Belgrade, SerbiaEmail: lkandolfsekulovic@gmail.com

Roland Kaufmann, MDProfessor of Dermatology, Director Department of DermatologyClinical Center J. W. Goethe University Theodor-Stern-Kai 7Frankfurt/Main, GermanyEmail: kaufmann@em.uni-frankfurt.de

Harald Kittler, MDDepartment of DermatologyMedical University of ViennaWaehringer Guertel 18–20Vienna, Austria Email: harald.kittler@meduniwien.ac.at

L

Aimilios Lallas, MDAristotle University of ThessaloikiDepartment of DermatologyThessaloniki, GreeceEmail: emlallas@gmail.com

Celeste Lebbé, MDProfessor of DermatologyDepartment of DermatologyHôpital Saint-Louis1, Avenue Claude-VellefauxParis, FranceEmail: celeste.lebbe@aphp.fr

Ulrike Leiter, MDProfessor of DermatologyDepartment of DermatologyEberhard Karls UniversityLiebermeister Str. 25Tuebingen, GermanyEmail: ulrike.leiter@med.uni-tuebingen.de

12

M

Josep Malvehy, MDDirector of the Melanoma Unit Department of Dermatology Hospital Clinic of Barcelona C/Villarroel 170Barcelona, SpainEmail: jmalvehy@clinic.ub.es

David Moreno-Ramirez, MDUniversity Hospital Virgen MacarenaCalle Dr. Fedriani, 3Seville, SpainEmail: dmoreno@e-derma.org

O

Judit Oláh, MD Department of DermatologyUniversity of SzegedKoranyi Fasor 6Szeged, HungaryEmail: dr.olah.judit@gmail.com

P

Ketty Peris, MDDepartment of DermatologyCatholic University of RomeLargo a Gemelli, 8Rome, ItalyEmail: ketty.peris@rm.unicatt.it

T

Franz Trautinger, MDUniversity Hospital St. PöltenHead of DermatologyDunant-Platz 1St. Pölten, AustriaEmail: franz.trautinger@stpoelten.lknoe.at

Z

Iris Zalaudek, MDHead of the Dermatology ClinicUniversity of TriesteHospital MaggiorePiazza dell' Ospedale 1Trieste, ItalyEmail: iris.zalaudek@gmail.com

13

General Information

Cancellation PolicyCancellations must be received in writing by December 18, 2020. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each can-celled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unex-pected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Course Organization

MedConcept Gesellschaft für medizinische Projekte mbH Friedenstraße 58 15366 Neuenhagen b. Berlin, Germany Phone: +49 (0)3342 42689-30 Fax: +49 (0)3342 42689-40 E-Mail: info@medconcept.org www.medconcept.org

FeeRegistration Fee of 120 Euro (incl. VAT)

Language and TranslationThe official language of the meeting will be English. Simultaneous translation will not be provided.